177 related articles for article (PubMed ID: 34545668)
1. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Kakotrichi P; Michailidis T; Liakos A; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2022 Jan; 24(1):106-114. PubMed ID: 34545668
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Musso G; Gambino R; Cassader M; Paschetta E
BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
[TBL] [Abstract][Full Text] [Related]
3. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Pasqualotto E; Figueiredo Watanabe JM; Gewehr DM; da Silva Maintinguer R; van de Sande-Lee S; de Araujo GN; Leal FS; Pinheiro CEA
Diabetes Obes Metab; 2023 Jul; 25(7):1794-1802. PubMed ID: 36929659
[TBL] [Abstract][Full Text] [Related]
6. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
10. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
11. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
12. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials.
Wu J; Zhao X; Chen H; Zhu S
J Diabetes Complications; 2022 Dec; 36(12):108352. PubMed ID: 36370667
[TBL] [Abstract][Full Text] [Related]
14. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Seidu S; Kunutsor SK; Topsever P; Khunti K
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
[TBL] [Abstract][Full Text] [Related]
15. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
[TBL] [Abstract][Full Text] [Related]
18. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Baker C; Wason S; Banks P; Sawhney S; Chang A; Danne T; Gesty-Palmer D; Kushner JA; McGuire DK; Mikell F; O'Neill M; Peters AL; Strumph P
Diabetes Obes Metab; 2019 Nov; 21(11):2440-2449. PubMed ID: 31264767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
